Tue - July 28, 2026
9:34 am
|
Article Hits:1623
Feasibility randomized controlled trial by Seliger et al. | Journal of the American Society of Nephrology | Published online ahead of print on 24 October 2026. pubmed.ncbi.nlm.nih.gov
In a 12-month randomized trial of 50 adults at high risk of rapid ADPKD progression, height-adjusted total kidney volume increased by 10.5% per year with empagliflozin versus 5.1% with placebo. Participants generally tolerated the drug. After an initial decline in estimated glomerular filtration rate (eGFR), the difference in eGFR slope over months 1–12 was statistically inconclusive
MORE